WO2001091797A3 - Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen - Google Patents

Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen Download PDF

Info

Publication number
WO2001091797A3
WO2001091797A3 PCT/EP2001/005169 EP0105169W WO0191797A3 WO 2001091797 A3 WO2001091797 A3 WO 2001091797A3 EP 0105169 W EP0105169 W EP 0105169W WO 0191797 A3 WO0191797 A3 WO 0191797A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
group
erythrocytes
substances
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/005169
Other languages
English (en)
French (fr)
Other versions
WO2001091797A2 (de
Inventor
Walter Elger
Alexander Hillisch
Annemarie Hedden
Sigfrid Schwarz
Klaus Schoellkopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7644802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001091797(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP01943329A priority Critical patent/EP1294402B2/de
Priority to PL361426A priority patent/PL206462B1/pl
Priority to AU6593301A priority patent/AU6593301A/xx
Priority to CA002410630A priority patent/CA2410630A1/en
Priority to BR0111294-5A priority patent/BR0111294A/pt
Priority to SK291-2003A priority patent/SK2912003A3/sk
Priority to AU2001265933A priority patent/AU2001265933B2/en
Priority to DK01943329T priority patent/DK1294402T4/da
Priority to MXPA02011844A priority patent/MXPA02011844A/es
Priority to HR20021038A priority patent/HRP20021038B1/xx
Priority to IL15293201A priority patent/IL152932A0/xx
Priority to MEP-146/08A priority patent/MEP14608A/xx
Priority to HU0301949A priority patent/HUP0301949A3/hu
Priority to US10/296,973 priority patent/US7507725B2/en
Priority to JP2001587809A priority patent/JP2003534386A/ja
Priority to EA200201201A priority patent/EA006432B1/ru
Priority to DE50108674T priority patent/DE50108674D1/de
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Priority to UA20021210409A priority patent/UA76953C2/uk
Publication of WO2001091797A2 publication Critical patent/WO2001091797A2/de
Publication of WO2001091797A3 publication Critical patent/WO2001091797A3/de
Priority to IL152932A priority patent/IL152932A/en
Priority to NO20025739A priority patent/NO20025739L/no
Anticipated expiration legal-status Critical
Priority to BG107556A priority patent/BG107556A/bg
Priority to US12/142,332 priority patent/US20090023896A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Die vorliegende Erfindung betrifft Verbindungen, die als Prodrug und/oder Träger die Aufnahme eines Wirkstoffs in die Erythrozyten und/oder die Bindung eines Wirkstoffs an die Erythrozyten ermöglichen, wobei die Aufnahme der Verbindungen in und/oder die Bindung der Verbindungen an die Erythrozyten durch eine Gruppe -SO2NR1R2 ermöglicht wird, wobei R?1 und R2¿ unabhängig voneinander ein Wasserstoffatom, eine Acylgruppe, eine Alkylgruppe, eine Cycloalkylgruppe, eine Arylgruppe, eine Cyanogruppe oder eine Hydroxygruppe bedeuten. Durch die erfindungsgemäßen Prodrugs werden Wirkstoffe, wie körpereigene Substanzen, Naturstoffe und synthetische Substanzen mit therapeutisch wertvollen Eigenschaften mit hohem 'first pass' Effekt sinnvoll oral verfügbar gemacht bzw. bezüglich oraler Aktivität entscheidend verbessert.
PCT/EP2001/005169 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen Ceased WO2001091797A2 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
PL361426A PL206462B1 (pl) 2000-05-31 2001-05-08 Związek jako prolek lub nośnik umożliwiający wprowadzenie substancji czynnej do erytrocytów i jego zastosowanie
HU0301949A HUP0301949A3 (en) 2000-05-31 2001-05-08 Compounds with a sulfonamide group and pharmaceutical compositions containing these compounds
AU6593301A AU6593301A (en) 2000-05-31 2001-05-08 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
CA002410630A CA2410630A1 (en) 2000-05-31 2001-05-08 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
BR0111294-5A BR0111294A (pt) 2000-05-31 2001-05-08 Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos
SK291-2003A SK2912003A3 (en) 2000-05-31 2001-05-08 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
AU2001265933A AU2001265933B2 (en) 2000-05-31 2001-05-08 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
DK01943329T DK1294402T4 (da) 2000-05-31 2001-05-08 Forbindelser med en sulfonamidgruppe og farmaceutiske præparater indeholdende disse forbindelser
MXPA02011844A MXPA02011844A (es) 2000-05-31 2001-05-08 Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos.
HR20021038A HRP20021038B1 (hr) 2000-05-31 2001-05-08 Spojevi sa sulfonamidnom grupom i farmaceutske smjese koje sadrže te spojeve
IL15293201A IL152932A0 (en) 2000-05-31 2001-05-08 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
JP2001587809A JP2003534386A (ja) 2000-05-31 2001-05-08 スルホンアミド基を有する化合物及びこれらの化合物を含む医薬組成物
US10/296,973 US7507725B2 (en) 2000-05-31 2001-05-08 Compounds with sulphonamide group and pharmaceutical compositions containing these compounds
EP01943329A EP1294402B2 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen
MEP-146/08A MEP14608A (bs) 2000-05-31 2001-05-08 Jedinjenja sa sulfonamidnom grupom i farmaceutski sastavi koji sadrže ova jedinjenja
EA200201201A EA006432B1 (ru) 2000-05-31 2001-05-08 Соединения с сульфамидной группой и содержащие эти соединения фармацевтические композиции
DE50108674T DE50108674D1 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen
UA20021210409A UA76953C2 (en) 2000-05-31 2001-08-05 Substance containing sulfamide group and its use for preparing drug providing for depot effect
IL152932A IL152932A (en) 2000-05-31 2002-11-19 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
NO20025739A NO20025739L (no) 2000-05-31 2002-11-29 Forbindelser med en sulfonamidgruppe og farmasöytiske preparater som inneholder disse forbindelsene
BG107556A BG107556A (bg) 2000-05-31 2003-02-14 Съединения, съдържащи сулфонамидна група, и фармацевтични състави, които ги съдържат
US12/142,332 US20090023896A1 (en) 2000-05-31 2008-06-19 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10027887A DE10027887A1 (de) 2000-05-31 2000-05-31 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10027887.6 2000-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/142,332 Continuation US20090023896A1 (en) 2000-05-31 2008-06-19 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds

Publications (2)

Publication Number Publication Date
WO2001091797A2 WO2001091797A2 (de) 2001-12-06
WO2001091797A3 true WO2001091797A3 (de) 2002-06-20

Family

ID=7644802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005169 Ceased WO2001091797A2 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Country Status (29)

Country Link
US (2) US7507725B2 (de)
EP (1) EP1294402B2 (de)
JP (1) JP2003534386A (de)
KR (3) KR20080038460A (de)
CN (1) CN1441678A (de)
AT (1) ATE315407T1 (de)
AU (2) AU2001265933B2 (de)
BG (1) BG107556A (de)
BR (1) BR0111294A (de)
CA (1) CA2410630A1 (de)
CZ (1) CZ2003621A3 (de)
DE (2) DE10027887A1 (de)
DK (1) DK1294402T4 (de)
EA (1) EA006432B1 (de)
ES (1) ES2256256T5 (de)
HR (1) HRP20021038B1 (de)
HU (1) HUP0301949A3 (de)
IL (2) IL152932A0 (de)
ME (1) MEP14608A (de)
MX (1) MXPA02011844A (de)
NO (1) NO20025739L (de)
NZ (1) NZ535201A (de)
PL (1) PL206462B1 (de)
PT (1) PT1294402E (de)
SK (1) SK2912003A3 (de)
UA (1) UA76953C2 (de)
WO (1) WO2001091797A2 (de)
YU (1) YU90102A (de)
ZA (1) ZA200209490B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US20050282793A1 (en) * 2004-05-21 2005-12-22 Ralf Wyrwa Steroid prodrugs with androgenic action
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
DE102004025986A1 (de) * 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057225A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
DE102005057421A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Heteroaromatische Sulfonamid-Prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8777182B2 (en) 2008-05-20 2014-07-15 Grinon Industries Fluid transfer assembly and methods of fluid transfer
EP2285687B1 (de) 2008-05-20 2016-03-16 Grinon Industries Flüssigkeitstransferanordnung und verfahren für flüssigkeitstransfer
US9100458B2 (en) * 2008-09-11 2015-08-04 At&T Intellectual Property I, L.P. Apparatus and method for delivering media content
CN101987102A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种糖皮质激素杂芳香基氨磺酰基羧酸酯的眼用抗炎组合物
CN101987104A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物
EP2797833B1 (de) 2011-12-30 2016-08-03 Grinon Industries Flüssigkeitstransferanordnung und verfahren für flüssigkeitstransfer
PE20160655A1 (es) * 2013-07-11 2016-07-08 Evestra Inc Profarmacos de formacion de compuestos
JP6924756B2 (ja) 2015-11-27 2021-08-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング キャップをもつ薬物送達デバイス
EP3173113A1 (de) * 2015-11-27 2017-05-31 Sanofi-Aventis Deutschland GmbH Injektionsnadelanordnung
US10624903B2 (en) 2017-10-19 2020-04-21 Evestra, Inc. Longer-acting progestin prodrug contraceptives
CN116568672B (zh) * 2020-11-17 2026-03-24 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1203042B (de) * 1963-11-21 1965-10-14 Schering Ag Fungizide Mittel
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5025031A (en) * 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
WO1993005064A1 (en) * 1991-08-29 1993-03-18 Imperial College Of Science, Technology And Medicine Steroid sulphatase inhibitors
WO1994014827A1 (en) * 1992-12-22 1994-07-07 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
WO1994026702A1 (en) * 1993-05-14 1994-11-24 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1996005216A1 (de) * 1994-08-09 1996-02-22 Jenapharm Gmbh Estra-1,3,5(10)-trien-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO1997014712A2 (de) * 1995-10-19 1997-04-24 Jenapharm Gmbh Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2000006475A1 (en) * 1998-07-29 2000-02-10 Crisplant A/S Parcel singulation system
WO2001051055A2 (en) * 2000-01-14 2001-07-19 Sterix Limited Pharmaceutical compositions containing steroidal structures and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593609A (en) 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
US4244940A (en) * 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4447714C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
US5705495A (en) * 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19712488A1 (de) 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US6583130B1 (en) 1999-09-13 2003-06-24 Schering Ag C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
BR0109983A (pt) 2000-04-12 2003-02-25 Schering Ag Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
JP2004532838A (ja) 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
WO2002076464A1 (en) * 2001-03-22 2002-10-03 Arena Pharmaceuticals, Inc. Anti-psychosis combination
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
DE10226326A1 (de) 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
ES2307064T3 (es) 2003-11-26 2008-11-16 Bayer Schering Pharma Aktiengesellschaft Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol.
DE102004025986A1 (de) 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
DE102004025966A1 (de) 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US20050277625A1 (en) 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025985A1 (de) 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1203042B (de) * 1963-11-21 1965-10-14 Schering Ag Fungizide Mittel
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5025031A (en) * 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
WO1993005064A1 (en) * 1991-08-29 1993-03-18 Imperial College Of Science, Technology And Medicine Steroid sulphatase inhibitors
WO1994014827A1 (en) * 1992-12-22 1994-07-07 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
WO1994026702A1 (en) * 1993-05-14 1994-11-24 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1996005216A1 (de) * 1994-08-09 1996-02-22 Jenapharm Gmbh Estra-1,3,5(10)-trien-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO1997014712A2 (de) * 1995-10-19 1997-04-24 Jenapharm Gmbh Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2000006475A1 (en) * 1998-07-29 2000-02-10 Crisplant A/S Parcel singulation system
WO2001051055A2 (en) * 2000-01-14 2001-07-19 Sterix Limited Pharmaceutical compositions containing steroidal structures and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARTH A ET AL: "INFLUENCE OF SUBCHRONIC ADMINISTRATION OF OESTRADIOL, ETHINYLOESTRADIOL AND OESTRADIOL SULPHAMATE ON BILE FLOW, BILE ACIDEXCRETION, AND LIVER AND BILIARY GLUTATHIONE STATUS IN RATS", ARCHIVES OF TOXICOLOGY, SPRINGER VERLAG, DE, vol. 71, no. 7, 1997, pages 443 - 449, XP000986430, ISSN: 0340-5761 *
ELGER W ET AL: "SULFAMATES OF VARIOUS ESTROGENS ARE PRODRUGS WITH INCREASED SYSTEMIC AND REDUCED HEPATIC ESTROGENICITY AT ORAL APPLICATION", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 55, no. 3/4, 1995, pages 395 - 403, XP000618892, ISSN: 0960-0760 *
MARYANOFF B E ET AL: "ANTICONVULSANT SUGAR SULFAMATES. POTENT CYCLIC SULFATE AND CYCLIC SULFITE ANALOGUES OF TOPIRAMATE", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 3, no. 12, 1993, pages 2653 - 2656, XP000914306, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2001091797A2 (de) 2001-12-06
EP1294402B1 (de) 2006-01-11
NZ535201A (en) 2007-01-26
US20090023896A1 (en) 2009-01-22
HRP20021038A2 (en) 2004-10-31
YU90102A (sh) 2006-05-25
KR20080038460A (ko) 2008-05-06
CZ2003621A3 (cs) 2003-12-17
NO20025739D0 (no) 2002-11-29
MXPA02011844A (es) 2004-05-17
PL206462B1 (pl) 2010-08-31
ES2256256T3 (es) 2006-07-16
DE50108674D1 (de) 2006-04-06
IL152932A (en) 2007-07-04
NO20025739L (no) 2002-11-29
JP2003534386A (ja) 2003-11-18
EA006432B1 (ru) 2005-12-29
HUP0301949A2 (hu) 2003-09-29
US7507725B2 (en) 2009-03-24
ZA200209490B (en) 2005-03-10
PL361426A1 (pl) 2004-10-04
US20040014781A1 (en) 2004-01-22
HRP20021038B1 (hr) 2008-08-31
EP1294402B2 (de) 2009-08-12
DK1294402T4 (da) 2009-11-23
PT1294402E (pt) 2006-05-31
HUP0301949A3 (en) 2010-01-28
CN1441678A (zh) 2003-09-10
BG107556A (bg) 2004-01-30
DE10027887A1 (de) 2001-12-13
AU6593301A (en) 2001-12-11
CA2410630A1 (en) 2002-11-28
SK2912003A3 (en) 2003-09-11
EP1294402A2 (de) 2003-03-26
MEP14608A (bs) 2010-06-10
DK1294402T3 (da) 2006-05-22
ATE315407T1 (de) 2006-02-15
UA76953C2 (en) 2006-10-16
AU2001265933B2 (en) 2007-10-18
IL152932A0 (en) 2003-06-24
KR20030017524A (ko) 2003-03-03
EA200201201A1 (ru) 2003-06-26
KR20090090398A (ko) 2009-08-25
ES2256256T5 (es) 2009-12-11
BR0111294A (pt) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2001091797A3 (de) Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2002011676A3 (en) Method of using diketopiperazines and composition containing them
MY132073A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
PT928788E (pt) Compostos farmaceuticamente activos
WO2003000194A3 (en) Thienopyridine and thienopyrimidine anticancer agents
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
EP1182193A4 (de) Medikamente gegen neuropathische schmerzen
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
EP1228072A4 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
NO173700C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte aminoalkosybenzenderivater
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2003049676A3 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
WO1996023771A3 (en) Platelet aggregation inhibitors
WO1999011651A3 (en) 3-descladinose 6-o-substituded erythromycin derivatives
WO2002011740A3 (en) 'slow release' pharmaceutical compositions comprising lithium carbonate
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson
BR0109573A (pt) Composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo, agente, composição farmacêutica, e, uso de um composto ou uma pró-droga ou um sal farmacologicamente aceitável do mesmo
WO2000010543A3 (de) Arzneimittel enthaltend platinkomplexverbindungen sowie deren verwendung
WO2001053322A3 (en) Aerothricin analogs, their preparation and use
BRPI0411043A (pt) composição medicinal

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-901/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AU BA BB BG BR CA CN CO CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LS MA MG MN MX NO NZ PL SG SK TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AU BA BB BG BR CA CN CO CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LS MA MG MN MX NO NZ PL SG SK TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 152932

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/09490

Country of ref document: ZA

Ref document number: 200209490

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 522769

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01675/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020027016148

Country of ref document: KR

Ref document number: 2410630

Country of ref document: CA

Ref document number: 018103375

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 587809

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011844

Country of ref document: MX

Ref document number: 02108566

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200201201

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2001943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001265933

Country of ref document: AU

Ref document number: P20021038A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 10755601

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2003-621

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020027016148

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2912003

Country of ref document: SK

WWP Wipo information: published in national office

Ref document number: 2001943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296973

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-621

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001943329

Country of ref document: EP